AstraZeneca PLC (STO:AZN)
1,377.00
-14.50 (-1.04%)
May 6, 2025, 5:00 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Oncology | 20.28B |
Log In |
Log In |
Log In |
Log In |
Oncology Growth | 18.26% |
Log In |
Log In |
Log In |
Log In |
BioPharmaceuticals: CVRM | 12.45B |
Log In |
Log In |
Log In |
Log In |
BioPharmaceuticals: CVRM Growth | 17.60% |
Log In |
Log In |
Log In |
Log In |
BioPharmaceuticals: R&I | 7.42B |
Log In |
Log In |
Log In |
Log In |
BioPharmaceuticals: R&I Growth | 21.43% |
Log In |
Log In |
Log In |
Log In |
Other Medicines | 1.07B |
Log In |
Log In |
Log In |
Log In |
Other Medicines Growth | -8.67% |
Log In |
Log In |
Log In |
Log In |
COVID-19 | - |
Log In |
Log In |
Log In |
Log In |
COVID-19 Growth | - |
Log In |
Log In |
Log In |
Log In |
Collaboration | 3.14B |
Log In |
Log In |
Log In |
Log In |
Collaboration Growth | 55.04% |
Log In |
Log In |
Log In |
Log In |
BioPharmaceuticals V&I | 1.06B |
Log In |
Log In |
Log In |
Log In |
BioPharmaceuticals V&I Growth | 4.45% |
Log In |
Log In |
Log In |
Log In |
Rare Disease | 8.67B |
Log In |
Log In |
Log In |
Log In |
Rare Disease Growth | 11.64% |
Log In |
Log In |
Log In |
Log In |
Capex by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
UK Assets Acquired | 582.00M |
Log In |
Log In |
Log In |
Log In |
UK Assets Acquired Growth | - |
Log In |
Log In |
Log In |
Log In |
Rest of Europe Assets Acquired | 2.23B |
Log In |
Log In |
Log In |
Log In |
Rest of Europe Assets Acquired Growth | - |
Log In |
Log In |
Log In |
Log In |
The Americas Assets Acquired | 3.93B |
Log In |
Log In |
Log In |
Log In |
The Americas Assets Acquired Growth | - |
Log In |
Log In |
Log In |
Log In |
Asia, Africa & Australasia Assets Acquired | 1.39B |
Log In |
Log In |
Log In |
Log In |
Asia, Africa & Australasia Assets Acquired Growth | - |
Log In |
Log In |
Log In |
Log In |
EBIT by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
UK Operating Profit | 2.68B |
Log In |
Log In |
Log In |
Log In |
UK Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In |
Rest of Europe Operating Profit | 5.92B |
Log In |
Log In |
Log In |
Log In |
Rest of Europe Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In |
The Americas Operating Profit | 423.00M |
Log In |
Log In |
Log In |
Log In |
The Americas Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In |
Asia, Africa & Australasia Operating Profit | 976.00M |
Log In |
Log In |
Log In |
Log In |
Asia, Africa & Australasia Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
UK Revenue | 4.74B |
Log In |
Log In |
Log In |
Log In |
UK Revenue Growth | - |
Log In |
Log In |
Log In |
Log In |
Rest of Europe | 11.70B |
Log In |
Log In |
Log In |
Log In |
Rest of Europe Growth | - |
Log In |
Log In |
Log In |
Log In |
The Americas | 24.99B |
Log In |
Log In |
Log In |
Log In |
The Americas Growth | - |
Log In |
Log In |
Log In |
Log In |
Asia, Africa & Australasia | 12.64B |
Log In |
Log In |
Log In |
Log In |
Asia, Africa & Australasia Growth | - |
Log In |
Log In |
Log In |
Log In |